The excretory/secretory (ES) materials from filarial parasites form an important tool for immunodiagnosis of filariasis. We have raised monoclonal antibodies against ES proteins isolated from the medium incubated with live adult bovine filarial parasite Setaria digitata. The hybridoma were cloned and characterised with respect to the individual proteins of the ES materials. A secretory glycoprotein with molecular weight 200-kDa (gp200) was purified, localised and characterised using the specific monoclonal antibodies raised against it. The immunolocalisation study clearly showed that the protein is secreted out through the pores on the surface of both male and female parasites. The gp200 on reduced sodium dodecyl sulphate-polyacrylamide gel electrophoresis showed dissociation into 11- to 66-kDa 'ladder' polypeptides, and all of them could be identified with the same monoclonal antibody. The gp200 is normally shed along with the ES materials. The screening of human sera samples using the monoclonal antibodies give promising results which showed that gp200 could be a potent candidate protein for the immunodiagnosis of filariasis by the method of antigen detection.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00436-009-1525-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of CGRP monoclonal antibody treatment on blood pressure in patients with migraine: A systematic review and potential clinical implications.
Cephalalgia
January 2025
Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands.
Background: Monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) or the CGRP-receptor have revolutionized the prevention of migraine. Despite their effectiveness, worries have surfaced regarding potential unwanted cardiovascular effects linked to the vasodilation function of CGRP, suggesting a potential influence on blood pressure (BP).
Methods: Studies were systematically retrieved from PubMed, Cochrane Database of Systematic Reviews, Web of Science, MEDLINE and EMBASE up to 1 May 2024.
Biologic Therapies for Chronic Obstructive Pulmonary Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
COPD
December 2025
Division of Respirology, Department of Medicine, McMaster University, Hamilton, ON, Canada.
Background: Despite limited breakthroughs in COPD pharmacotherapy, recent trials have shown promising results for biologics in COPD patients. However, robust evidence synthesis in this area is currently lacking.
Methods: We conducted a systematic review of MEDLINE, EMBASE, and Cochrane CENTRAL from inception to July 17, 2024, to identify randomized trials of biologic medications in patients with COPD.
Pembrolizumab as first-line treatment for recurrent and metastatic head and neck cancer - real-world single-centre data.
Acta Oncol
January 2025
Department of Oncology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Background And Purpose: The randomised clinical trial KEYNOTE-048 has demonstrated a significant increase in survival for patients with head and neck cancer treated with pembrolizumab with or without chemotherapy. The purpose of the present retrospective study was to investigate whether survival in a group of consecutive patients treated at our department was comparable to the results from KEYNOTE-048.
Patients/material And Methods: Seventy-six patients initiated treatment with pembrolizumab ± platinum/5-FU between July 2020 and May 2022.
IQ Survey Results on Current Industry Practices-Part 1: Immunogenicity Risk Assessment.
Clin Pharmacol Ther
January 2025
Clinical Pharmacology, Genentech/Roche, South San Francisco, California, USA.
An immunogenicity risk assessment (IRA) is a relatively new expectation of health authorities that is increasingly incorporated into the drug development process across the pharmaceutical/biotech industry. The guiding principle for an IRA includes a comprehensive evaluation of product- and patient-related factors that may influence the immunogenic potential of a biotherapeutic drug and a potential action plan. The Immunogenicity Working Group from the IQ Consortium (Clinical Pharmacology Leadership Group) has conducted a survey to understand the current practices for conducting IRAs and relevant aspects of bioanalysis.
View Article and Find Full Text PDFEfficacy and safety of neoadjuvant bevacizumab plus chemotherapy in locally advanced gastric cancer patients: a retrospective, comparative study.
World J Surg Oncol
January 2025
Colorectal Surgery Department, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/ Hunan Cancer Hospital, No. 283 Tongzipo Road, Yuelu District, Changsha, Hunan, 410013, China.
Objective: The clinical benefits of neoadjuvant bevacizumab plus chemotherapy in locally advanced gastric cancer patients are controversial. This study intended to evaluate the efficacy and safety of neoadjuvant bevacizumab plus chemotherapy in these patients.
Methods: In this retrospective study, 71 locally advanced gastric cancer patients receiving neoadjuvant bevacizumab plus chemotherapy or neoadjuvant chemotherapy alone were divided into bevacizumab plus chemo group (N = 23) and chemo group (N = 48).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!